Key points are not available for this paper at this time.
This Viewpoint discusses how the price negotiation for certain drugs under the Inflation Reduction Act will provide a unique opportunity to enhance access to therapies for older patients with cardiovascular conditions and diabetes.
Kazi et al. (Wed,) studied this question.